Lebrikizumab clinical trials
Also written LY3650150, DRM06 and Ebglyss.
How each study uses lebrikizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lebrikizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Sept 2024 · EBGLYSS · BLA 761306 (FDA, Drugs@FDA)
- European Union
- 16 Nov 2023 · Ebglyss · EMEA/H/C/005894 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 44 · Other 4
Eli Lilly and Company (19) · Hoffmann-La Roche (11) · Genentech, Inc. (7) · Almirall, S.A. (6) · Johann E Gudjonsson MD PhD (1) · Forefront Dermatology S.C (1) · University of Maryland, Baltimore (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Pirfenidone (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 2 in phase 3
Studies that test lebrikizumab, phase 3 first.
- Apr 2027A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisPhase 3 · Almirall, S.A.
- May 2027A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)Phase 3 · Eli Lilly and Company
- Jul 2027Lebrikizumab in Moderate-to-severe Atopic DermatitisPhase 4 · Johann E Gudjonsson MD PhD
- Aug 2027AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered OutcomesPhase 4 · Forefront Dermatology S.C
Studies
Open first, then newest update. How each study uses lebrikizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 48
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)RecruitingPhase 3Eli Lilly and CompanyNCT06338995Written as LY3650150
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEnrolling by invitationPhase 3Eli Lilly and CompanyNCT05735483Written as Lebrikizumab
- A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic DermatitisNot yet recruitingPhase 3Almirall, S.A.NCT07873801Written as Lebrikizumab
- AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered OutcomesNot yet recruitingPhase 4Forefront Dermatology S.CNCT07856134Written as Lebrikizumab-lbkz
- Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis PatientsNot yet recruitingPhase 2University of Maryland, BaltimoreNCT07620561Written as Lebrikizumab
- A Study of Lebrikizumab in Adults With Nummular EczemaRecruitingPhase 3Almirall, S.A.NCT07542483Written as Lebrikizumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Lebrikizumab
- A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent AsthmaTerminatedPhase 2Hoffmann-La RocheNCT01987492Written as Lebrikizumab
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06339008Written as LY3650150
- A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Eli Lilly and CompanyNCT06280716Written as Lebrikizumab
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch BurdenCompletedPhase 4Eli Lilly and CompanyNCT07006792Written as Lebrikizumab
- Lebrikizumab in Moderate-to-severe Atopic DermatitisActive, not recruitingPhase 4Johann E Gudjonsson MD PhDNCT06906497Written as lebrikizumab
- A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Hoffmann-La RocheNCT02546700Written as Lebrikizumab
- A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisCompletedPhase 3Eli Lilly and CompanyNCT06921759Written as Lebrikizumab
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisActive, not recruitingPhase 3Eli Lilly and CompanyNCT05559359Written as Lebrikizumab
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaCompletedPhase 3Hoffmann-La RocheNCT02104674Written as Lebrikizumab
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationCompletedPhase 3Hoffmann-La RocheNCT01867125Written as Lebrikizumab
- Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Almirall, S.A.NCT05990725Written as Lebrikizumab
- A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationTerminatedPhase 3Hoffmann-La RocheNCT01875003Written as Lebrikizumab
- Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Almirall, S.A.NCT05916365Written as Lebrikizumab
See all 48 studies that test lebrikizumab →
As the comparator · 1 — what is tested is compared with lebrikizumab
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Stopped1
- A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent AsthmaTerminatedNov 10, 2026NCT01987492
Codes
What other systems call lebrikizumab · ClinicalTrials.gg INT005906
- MeSH (NLM) C561806lebrikizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U9JLP7V031LEBRIKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3829321lebrikizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87767LebrikizumabOne source FDA
- DrugBank DB11914One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561806 | lebrikizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U9JLP7V031 | LEBRIKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3829321 | lebrikizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87767 | Lebrikizumab | One source FDA |
| DrugBank | DB11914 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.